UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Cancer treatment and research communications, 2021, Vol.26, p.100272-100272, Article 100272

2021

Link zum Volltext

Verfügbarkeit prüfen

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach

Frontiers in neurology, 2023-01, Vol.13, p.1034269-1034269

2023

Link zum Volltext

Verfügbarkeit prüfen

The Impact of Omalizumab Therapy on Sleep in Patients With Nasal Polyps

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB244-AB244

2021

Link zum Volltext

Verfügbarkeit prüfen

Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status

Annals of allergy, asthma, & immunology, 2024-03, Vol.132 (3), p.355-362.e1

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma

Annals of allergy, asthma, & immunology, 2022-05, Vol.128 (5), p.553-560

2022

Link zum Volltext

Verfügbarkeit prüfen

Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials

International forum of allergy & rhinology, 2024-07, Vol.14 (7), p.1163-1172

2024

Link zum Volltext

Verfügbarkeit prüfen

Age of asthma onset does not impact the response to omalizumab

Chronic respiratory disease, 2023-01, Vol.20, p.14799731231159673-14799731231159673

2023

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Influenza with Treatment in Patients with Diabetes: Subgroup Analysis of the Phase 3 CAPSTONE-2 Trial

Metabolism, clinical and experimental, 2021-03, Vol.116, p.154624, Article 154624

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

The lancet respiratory medicine, 2020-06, Vol.8 (6), p.561-572

2020

Link zum Volltext

Verfügbarkeit prüfen

Similar response to omalizumab in children with allergic asthma from different racial backgrounds

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2023-09, Vol.11 (9), p.2911-2913

2023

Link zum Volltext

Verfügbarkeit prüfen

Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial

Journal of asthma and allergy, 2023-01, Vol.16, p.661-665

2023

Link zum Volltext

Verfügbarkeit prüfen

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR -mutant non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9094-9094

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(12)

Sprache

Englisch
(12)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Allergy
(4)
Asthma
(4)
Humans
(4)
Immunoglobulin E
(4)
Immunology
(4)
Clinical Trials
(3)
Monoclonal Antibodies
(3)
Omalizumab - Therapeutic Use
(3)
Respiratory System
(3)
Omalizumab
(2)
Polyps
(2)
Rhinosinusitis
(2)
Sleep
(2)
Adult
(1)
Advanced Melanoma
(1)
Analysis
(1)
Anti-Asthmatic Agents - Pharmacology
(1)
Anti-Asthmatic Agents - Therapeutic Use
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach

The Impact of Omalizumab Therapy on Sleep in Patients With Nasal Polyps

Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status

Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma

Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials

Age of asthma onset does not impact the response to omalizumab

Outcomes of Influenza with Treatment in Patients with Diabetes: Subgroup Analysis of the Phase 3 CAPSTONE-2 Trial

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Similar response to omalizumab in children with allergic asthma from different racial backgrounds

Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR -mutant non-small cell lung cancer (NSCLC)

Suchergebnisse filtern